Browse the full directors' dealings record of Faeth Therapeutics, Inc., a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €644.5m. The latest transaction was disclosed on 26 June 2026 (Acquisition). Among the most active insiders: STEPHENSON BRIAN C. All data is accessible without an account.
19
Insider Decl.
0
Thresholds
·
17 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Faeth Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$54.50.
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.